Washington, September 28, 2026: The U.S. Food and Drug Administration has approved Atebrioz (zilurgisertib) for fibrodysplasia ossificans progressiva, or FOP.
New treatment option
The FDA listed the September 25 approval among its latest notable drug approvals. FOP is a rare disorder in which soft tissues can progressively turn into bone.
Rare disease treatment
The approval adds a third FDA-approved treatment option for patients with the condition. Patients should discuss treatment choices and potential risks with qualified healthcare professionals.
Source: FDA
Never miss a storyFollow News Nation Online on WhatsApp for breaking news from India and the world.
Internal: Health & Fitness | Science & Space
जालना, महाराष्ट्र और देश-दुनिया की ताज़ा खबरें
सीधे अपनी Facebook फ़ीड में पाएँ — News Nation Online पेज को Follow करें।
👍 Facebook पर Follow करेंसीधे अपनी Facebook फ़ीड में पाएँ — News Nation Online पेज को Follow करें।
Discover more from NewsNation Online
Subscribe to get the latest posts sent to your email.
आपके लिए सुझाव
